New oral GLP‑1 pill
Eli Lilly’s oral GLP‑1 weight‑loss pill Foundayo is now available in the U.S., giving people a noninjectable option that can be easier to fit into everyday life than shots. (prnewswire.com). Medical reporting notes the pill does not require strict timing or food rules, which could improve adherence for people who avoid injectable therapies. (medicalnewstoday.com)
Weight-loss drugs got famous as shots, but the newest entrant is a once-daily tablet called Foundayo, the brand name for Eli Lilly’s drug orforglipron, and U.S. prescriptions started shipping on April 6 after Food and Drug Administration approval on April 1, 2026. (fda.gov) (prnewswire.com) These drugs copy a gut hormone called glucagon-like peptide-1, which is one of the body’s “meal is coming” signals and helps people feel full sooner and stay full longer. Foundayo works on the same target as injectable drugs like Wegovy and Zepbound, but it comes as a swallowed tablet instead of a pen. (medicalnewstoday.com) (pi.lilly.com) The practical difference is not just “pill versus shot.” Lilly’s prescribing information says Foundayo can be taken at any time of day, with or without food and water, which is looser than the empty-stomach timing rules attached to some earlier oral glucagon-like peptide-1 medicines. (pi.lilly.com) (medicalnewstoday.com) That matters because obesity treatment often fails on routine, not chemistry. In Lilly’s launch materials, the company says adults with obesity or adults who are overweight and also have weight-related medical problems can use Foundayo alongside a reduced-calorie diet and more physical activity. (prnewswire.com) (pi.lilly.com) The pill is not a mild version of the shot. In the ATTAIN-1 trial program cited by Lilly and medical trade coverage, adults on the highest dose lost about 27 pounds on average, and placebo-adjusted weight loss across trials ran roughly 9 to 11 percentage points at 72 weeks. (prnewswire.com) (ajmc.com) The tradeoff looks familiar to anyone who has followed this class of drugs. The label lists nausea, diarrhea, vomiting, constipation, indigestion, and stomach pain among the most common side effects, which are the same stomach-and-gut problems that often show up when glucagon-like peptide-1 drugs slow digestion. (pi.lilly.com) The warning section is familiar too. Foundayo carries a boxed warning about thyroid C-cell tumors based on findings seen with glucagon-like peptide-1 drugs in rodents, and the label says it should not be used in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. (pi.lilly.com) (dailymed.nlm.nih.gov) This launch also changes the business fight around obesity drugs. Novo Nordisk already put an oral Wegovy on the U.S. market in January 2026, so Lilly is entering a race where the next battleground is not whether pills work, but which pill is easier to live with every day. (forbes.com) (msn.com) The approval itself was unusually fast. The Food and Drug Administration said Foundayo was cleared 50 days after filing and 294 days before its original Prescription Drug User Fee Act target date of January 20, 2027, making it the first new molecular entity approved under the agency’s Commissioner’s National Priority Voucher pilot program. (fda.gov) So the shift here is simple: the glucagon-like peptide-1 market now has a version that asks people to swallow one tablet a day instead of learning injection technique, storing pens, and planning around needle use. If adherence improves because the routine feels more like taking a blood-pressure pill than giving yourself a shot, Foundayo could pull a different group of patients into treatment than the injectable boom did. (medicalnewstoday.com) (prnewswire.com)
